Dr. Torti appointed to FDA leadership roles
The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.
The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.
Dr. Torti, who has written extensively on prostate and bladder cancer, is responsible for ensuring the quality and regulatory focus of the intramural research programs of the agency, with emphasis on clinical research trials.
He serves on the National Institutes of Health National Advisory Council for Complementary and Alternative Medicine, and is president of the Cancer Biology Training Consortium. He also is an NIH MERIT Award recipient.
Dr. Torti is the Charles L. Spurr Professor of Medicine, chair of the department of cancer biology, and director of the comprehensive cancer center at Wake Forest University School of Medicine in Winston-Salem, NC. He previously was on the faculty at Stanford University, Stanford, CA.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
